H. Müller

发表

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.

V. Diehl, P. Borchmann, A. Engert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

R. Spang, A. Rosenwald, W. Klapper, 2021, Leukemia.

Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma

A. Drzezga, M. Dietlein, C. Kobe, 2018, The Journal of Nuclear Medicine.

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

M. Dietlein, C. Kobe, P. Borchmann, 2022, BMC cancer.

Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)

A. Hüttmann, C. Kobe, P. Borchmann, 2021, British journal of haematology.

Survivors’ perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group

A. Mehnert, P. Borchmann, A. Engert, 2018, Leukemia & lymphoma.

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

A. Hüttmann, P. Borchmann, A. Engert, 2018, Leukemia.

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant

J. Glossmann, P. Borchmann, A. Engert, 2014, Leukemia & lymphoma.

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study Group

P. Borchmann, H. Flechtner, A. Engert, 2013, British Journal of Cancer.

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma

O. Casasnovas, M. Hutchings, P. Borchmann, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Early Response to First-Line Anti–PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial

M. Dietlein, C. Kobe, P. Borchmann, 2020, Clinical Cancer Research.

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

P. Borchmann, A. Engert, M. Fuchs, 2021, Leukemia.

Non‐Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group

V. Diehl, P. Borchmann, A. Engert, 2021, British journal of haematology.

R. Greil, V. Diehl, J. Bernhard, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

R. Greil, V. Diehl, P. Borchmann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials.

P. Borchmann, A. Engert, M. Fuchs, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude

A. Engert, S. Borchmann, H. Müller, 2017, Scientific Reports.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group.

H. Eich, R. Müller, V. Diehl, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group.

A. Engert, A. Balakumaran, P. Bröckelmann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The effect of specialized cancer treatment centers on treatment efficacy in Hodgkin's lymphoma.

N. Skoetz, P. Borchmann, A. Engert, 2012, Deutsches Arzteblatt international.

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude

A. Engert, S. Borchmann, H. Müller, 2017, Scientific Reports.

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

J. Raemaekers, N. Schmitz, D. Niederwieser, 2016, Leukemia & lymphoma.

Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study

P. Borchmann, U. Platzbecker, S. Kreissl, 2023, Journal of clinical psychology in medical settings.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease

V. Diehl, H. Gerhartz, K. Hübner, 1998 .

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

V. Diehl, J. Raemaekers, N. Schmitz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.